Seaport Therapeutics公布了其候选药物Glyphago™在健康受试者中进行的1期概念验证试验的多次递增剂量数据,结果积极。
该试验旨在评估Glyphago™在多次递增剂量下的安全性、耐受性及药代动力学特征。数据显示,在试验的剂量范围内,药物表现出良好的耐受性,未出现严重不良事件。同时,药代动力学参数符合预期,支持进一步的临床开发。
这些积极的初步数据为Glyphago™后续在目标患者群体中的研究奠定了基础。公司计划基于这些结果推进该项目的临床开发进程。
Seaport Therapeutics公布了其候选药物Glyphago™在健康受试者中进行的1期概念验证试验的多次递增剂量数据,结果积极。
该试验旨在评估Glyphago™在多次递增剂量下的安全性、耐受性及药代动力学特征。数据显示,在试验的剂量范围内,药物表现出良好的耐受性,未出现严重不良事件。同时,药代动力学参数符合预期,支持进一步的临床开发。
这些积极的初步数据为Glyphago™后续在目标患者群体中的研究奠定了基础。公司计划基于这些结果推进该项目的临床开发进程。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.